Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582051 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL3581397 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL12067856 | 0.77 | — | — | |
| SCHEMBL17290121 | 0.77 | — | — | |
| SCHEMBL574979 | 0.77 | — | — | |
| SCHEMBL29869257 | 0.77 | — | — | |
| SCHEMBL12424247 | 0.74 | FYN (0.37) | — | |
| SCHEMBL16975571 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL2695536 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL4536714 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | claimed |
| CN-116419753-A | Heterocyclic compounds as BCL-2 inhibitors | 北京诺诚健华医药科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| EP-4194454-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | claimed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | claimed |
| CN-114736203-A | Heterocyclic compounds as BCL-2 inhibitors | 南京天印健华医药科技有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114057728-A | Heterocyclic compounds as BCL-2 inhibitors | 北京诺诚健华医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | claimed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | claimed |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | claimed |
| EP-2820017-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | Genentech, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| EP-2812001-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-12-17 | — | — | EP | claimed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | claimed |
| EP-2638031-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| WO-2013127267-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | claimed |
| WO-2013130935-A1 | AMIDO-BENZYL SULFOXIDE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | claimed |
| WO-2013120104-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-08-15 | — | — | WO | claimed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | claimed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BCL2, BCL2L11, BCL2L2 | SMN1; SMN2 1829/4885 |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | SMN1; SMN2 3191/4885 |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | SMN1; SMN2 778/4885 |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | PHKG1, MAP4K5, HIPK1 | SMN1; SMN2 3099/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | SMN1; SMN2 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.